No open-market selling at Grace Therapeutics, Inc. in the past year, which is unusual. Instead two corporate insiders added about $474,000 worth of GRCE.
Biggest single buyer: Kohli Prashant, CEO, with roughly $214,000. That includes C-suite money, which tends to get the most attention.
33 investment managers listed GRCE in their latest 13F filings (Q2 2026); more funds bought than sold. Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 1,694 | $2.06 | $3K | SEC |
| Oct 5, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 38,796 | $2.04 | $79K | SEC |
| Oct 5, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 20,000 | $2.07 | $41K | SEC |
| Oct 1, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 5,318 | $2.10 | $11K | SEC |
| Oct 1, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 7,849 | $2.09 | $16K | SEC |
| Oct 1, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 9,771 | $2.10 | $21K | SEC |
| Sep 23, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 5,318 | $2.10 | $11K | SEC |
| Sep 23, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 9,771 | $2.10 | $21K | SEC |
| Sep 10, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 9,393 | $2.10 | $20K | SEC |
| Sep 10, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 5,836 | $2.09 | $12K | SEC |
| Sep 10, 2026 | Kohli Prashant | CEO | Buy | 100,000 | $2.14 | $214K | SEC |
| Aug 19, 2026 | Opaleye Management Inc. | 10% Owner | Buy | 11,608 | $2.09 | $24K | SEC |
In the last 12 months Grace Therapeutics, Inc. insiders made open-market purchases worth about $474,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in GRCE was filed on 2026-10-05.
33 investment managers reported holding GRCE in SEC Form 13F filings for Q2 2026.
No congressional trades in GRCE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).